At-home monitoring through telehealth may be a feasible form of care for prostate cancer patients receiving androgen deprivation therapy, according to a study published June 9 in JAMA Network Open.
Researchers from New York City-based Memorial Sloan Kettering Cancer Center enrolled 38 patients across seven ambulatory oncology practices between June 1, 2023, and June 30, 2024, to assess the implementation of enhanced telehealth.
Here are five things to know from the study:
- Patient-level completion rates were 68.4% for telehealth, 91.9% for remote blood pressure monitoring, 96.3% for home phlebotomy and 90% for at-home injections.
- Visit-level completion rates were 92.3% for telehealth, 95.4% for phlebotomy, 84.6% for injections and 65% for blood pressure monitoring.
- Patients rated the enhanced telehealth services as acceptable, appropriate and feasible.
- Patient and clinician satisfaction scores were high across all telehealth services.
- “In this quality improvement study, enhanced telehealth was feasible, with greater than 60% completion for all scheduled visits, with strong endorsement of benefits from patients with prostate cancer as well as clinicians,” the study authors wrote. “These findings support further development of enhanced telehealth.”
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
